Back from the brink

A new investor syndicate has rescued Cytos Biotechnology AG (SIX:CYTN) from the brink and is planning to plow up to CHF37 million ($40.3 million) into the Swiss biotech, which in the past eight months has nearly defaulted on its outstanding debt, suspended all R&D save for one molecule and announced a headcount reduction of nearly 90%.